Last reviewed · How we verify
PLX-PAD
PLX-PAD is a placental-derived cell therapy that promotes tissue repair and regeneration through anti-inflammatory and pro-angiogenic mechanisms.
PLX-PAD is a placental-derived cell therapy that promotes tissue repair and regeneration through anti-inflammatory and pro-angiogenic mechanisms. Used for Critical limb ischemia (CLI) / peripheral arterial disease, Acute myocardial infarction (AMI).
At a glance
| Generic name | PLX-PAD |
|---|---|
| Also known as | allogeneic Mesenchymal-like Adherent Stromal Cells (ASCs) |
| Sponsor | Pluristem Ltd. |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Vascular Disease |
| Phase | Phase 3 |
Mechanism of action
PLX-PAD consists of placental adherent cells that secrete bioactive factors including cytokines and growth factors that reduce inflammation, promote neovascularization, and enhance tissue healing. The cells work through paracrine signaling to modulate the immune response and stimulate endogenous repair mechanisms in damaged tissues.
Approved indications
- Critical limb ischemia (CLI) / peripheral arterial disease
- Acute myocardial infarction (AMI)
Common side effects
- Injection site reactions
- Fever
- Infection
Key clinical trials
- Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial (PHASE1, PHASE2)
- Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery (PHASE1, PHASE2)
- Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
- Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 (PHASE2)
- Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization (PHASE3)
- Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 (PHASE2)
- Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF) (PHASE3)
- Exosome Effect on Prevention of Hairloss (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLX-PAD CI brief — competitive landscape report
- PLX-PAD updates RSS · CI watch RSS
- Pluristem Ltd. portfolio CI